What Is the Difference Between a Supplement and a Medicine?

The category is set by what is claimed for a product and how it is presented, at least as much as by what is inside it. That is the answer most people find counter-intuitive, and it is the one that makes the rest of the system legible. Identical contents can sit in two different regulatory worlds depending on the sentence printed on the box and the way the product is put in front of a buyer.

It is worth saying immediately that this is not a loophole or an accident of drafting. Regulators built the boundary that way deliberately, because a claim is what a purchaser actually relies on. Somebody buying a product because it says it treats a condition is exposed to a risk that has nothing to do with the molecular contents and everything to do with the promise — and it is the promise that the medicines framework exists to test.

What follows describes how the two regimes are drawn, what each permits, why some product formats cannot cross between them at all, and where material supplied for research sits relative to both. It describes systems rather than advising on them, and it is not legal advice.

What is a food supplement allowed to claim?

Only claims about nutrition and about maintaining normal bodily function, and only from an authorised set — never that the product prevents, treats or cures a disease. That single restriction does more to separate the two categories than any rule about ingredients.

The starting definition is narrow and easy to miss. Food supplements are defined as foodstuffs whose purpose is to supplement the normal diet, which are concentrated sources of nutrients or other substances with a nutritional or physiological effect, and which are marketed in dose form — capsules, tablets, pastilles, sachets of powder, measured liquids and similar formats designed to be taken in small unit quantities 1. Every element of that sentence is load-bearing. They are foods. Their purpose is supplementation of a diet. They come in measured units.

The claims rules then sit on top. A separate regulation governs nutrition and health claims made on foods, establishing that claims must be authorised, must be supported by scientific assessment, and must fit within defined types 2. Reduction-of-disease-risk claims exist as a narrow authorised category with mandatory accompanying wording, but they are hedged precisely because they sit closest to the boundary 2. Straightforward claims that a food treats or cures disease are outside the framework entirely — a food making one is not a food making a bold claim, it is a product that has walked into the medicines regime.

So the honest summary of what a supplement may say is: it may say what it contains, it may carry authorised claims about nutrition and normal function, and it must stop there. The ceiling on claims is not a marketing inconvenience bolted onto the category. It is the category.

What turns a product into a medicine?

Either of two independent triggers, and only one of them has to fire. A product is a medicinal product if it is presented as having properties for treating or preventing disease in human beings, or if it is administered with a view to restoring, correcting or modifying physiological functions by pharmacological, immunological or metabolic action 3.

The first limb — presentation — is the one that catches products in practice, and it is remarkably unforgiving. It looks at how a product is put forward: the wording on packaging, the accompanying literature, the marketing, the context of sale. A product presented as treating a condition is a medicinal product by presentation whatever is actually inside it, which means the category can be triggered by a sentence alone. It also means the same physical product, marketed two different ways, can be two different regulatory objects.

The second limb — function — looks at what the product actually does when administered, assessed on evidence. Courts have been careful about how far it reaches, and the case law is instructive about how the boundary is policed in both directions. When a member state treated a garlic preparation in capsule form as a medicinal product requiring authorisation, the Court of Justice held that capsule form alone did not make it one, and that requiring a medicines authorisation in those circumstances was an unjustified restriction on the free movement of goods 4.

That judgment is worth holding alongside the claims rules, because together they show the boundary is genuinely two-sided. A national authority cannot simply annex borderline products into the medicines regime because they look pharmaceutical; and a seller cannot keep a product in the food regime while making claims that only a medicine may make. The line is patrolled from both directions.

Why can an injectable preparation never be a supplement?

Because the supplement category is defined around food taken by mouth, and injection is outside that definition before anyone even reaches the question of contents. This is not a judgement call at the margin; it is a definitional exclusion.

Walk back through the definition. A food supplement is a foodstuff, whose purpose is to supplement the normal diet, marketed in dose form and designed to be taken in small measured unit quantities 1. A preparation infused into a vein is not supplementing a diet in any sense the definition recognises, is not being consumed as food, and bypasses digestion entirely. Vitamins delivered intravenously are not a food that happens to arrive by a different door — the whole framing of the category has been left behind.

The medicines framework then picks the question up from the other side. Products intended for administration by injection are handled within the medicines regime, and placing a medicinal product on a market requires an authorisation granted after assessment of quality, safety and efficacy 3. There is no third category into which an injectable nutritional preparation can be filed, and this is the reason: one regime excludes it definitionally, and the other claims it.

The rationale is straightforward once stated. Injection removes the body's normal barriers — the gut wall, first-pass metabolism, the slow absorption that limits how fast anything reaches the circulation. It introduces risks that oral products simply do not carry: infection, infusion reactions, contamination and endotoxin, dosing errors that cannot be undone. Sterility, particulate limits and endotoxin control are pharmaceutical manufacturing problems, and the framework that assesses them is the medicines framework.

Has any regulator actually enforced this line?

Yes, and recently. In July 2026 the National Organisation for Medicines of Greece issued a public warning about preparations being presented, promoted and administered as dietary supplements under the general heading of intravenous therapy — injectable or infused solutions containing vitamins, minerals, amino acids or antioxidants 5.

The reasoning set out in that warning tracks the definitions almost exactly, which is what makes it a useful illustration rather than merely a news item. The authority stated that such preparations do not constitute dietary supplements, because supplements are intended solely to supplement the intake of a normal diet and are administered orally; that substances intended for intravenous injection are subject to pharmaceutical licensing and may not be circulated or marketed without a medicines authorisation granted after evaluation of quality, safety and efficacy; and that a product presented as having therapeutic or preventive properties is a medicine by virtue of its presentation 5.

The warning also identified the practical hazards it was concerned with — infections, allergic and anaphylactic reactions, and local or systemic complications from unassessed ingredients or impurities — and urged the public not to use injectable or intravenously infused preparations presented as dietary supplements, inviting reports of such practices 5.

Two features of this are worth noting for anyone trying to understand the boundary generally. The marketing claims cited in the warning were the familiar consumer-wellness vocabulary rather than anything overtly clinical, which shows how ordinary language can still constitute presentation as a medicine. And the action was directed at a category of practice rather than at particular contents — the objection was to a route of administration and a set of claims being fitted into a category that cannot hold them.

Where does research material sit relative to both?

Outside both, in a third channel that borrows the protections of neither. Material supplied for laboratory research is not a food supplement and is not a medicinal product, and it is important to be clear that this is a description of an absence rather than a middle position.

It is not a supplement because it is not a foodstuff, is not intended to supplement a diet, and is not supplied in a consumer dose form under food law 1. It is not a medicinal product because no therapeutic claim is made for it and no authority has assessed it for quality, safety or efficacy 3. The two exclusions are independent, and each holds on its own terms.

Set that beside the case-law point about how the boundary works in both directions, and one implication is sharper than people expect. The medicines regime's presentation limb does not care what channel something was sold through — a product presented as having properties for treating or preventing disease is caught by the definition regardless of the label it travelled under 3. Which is why research suppliers make no therapeutic claims: silence about use is what keeps material in the third channel rather than in the medicines regime it has not been assessed against.

The consequence for anyone reading a product page is a comparison worth making explicitly. A supplement has a claims ceiling and food-safety supervision. A medicine has an authorisation, an assessed indication, and a post-market safety system behind it. Research-supplied material has a supplier's own statement about contents, and after the point of sale there is no framework at all — no assessed indication, no route to report harm, no recall mechanism aimed at an end user.

None of which settles what is permitted where you are, and this page does not attempt to. Categories are defined nationally, enforcement is national, and the July 2026 warning discussed above is one authority acting under one country's law 5. The framework that governs your situation is your own jurisdiction's, and that is the only place an actual answer exists.